Department of Biology, Institute of Genetics, University of Erlangen-Nuremberg, Staudtstr. 5, 91058 Erlangen, Germany.
Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.
Intravenous immunoglobulin (IVIg) has been used for nearly three decades as an efficient anti-inflammatory therapeutic regimen in a growing number of autoimmune diseases. Despite this their success in clinical application, the mechanism of action of IVIg therapy remains elusive. During the last few years, several mechanisms dependent on either the IgG variable or constant fragment have been proposed to explain the potent immunomodulatory activity of IVIg. This review will discuss which molecular and cellular pathways might be involved in the anti-inflammatory activity of IVIg and for which types of autoimmune diseases they might be relevant.
静脉注射免疫球蛋白 (IVIg) 在近三十年中已被广泛应用于多种自身免疫性疾病的治疗,并取得了显著的疗效。尽管 IVIg 在临床应用中取得了成功,但其作用机制仍不明确。在过去的几年中,已经提出了几种依赖 IgG 可变区或恒定区的机制来解释 IVIg 的强大免疫调节活性。本综述将讨论 IVIg 的抗炎活性可能涉及哪些分子和细胞途径,以及它们对哪些类型的自身免疫性疾病可能具有相关性。